[논문]항결핵제 감수성 결핵에서의 내성 변화 추이

이규택; 정무상

doi:10.15324/kjcls.2021.53.2.137

항결핵제 감수성 결핵에서의 내성 변화 추이
The Patterns of Acquiring Anti-Mycobacterial Drug Resistance by Susceptible Strains of Mycobacterium tuberculosis 원문보기

Korean journal of clinical laboratory science : KJCLS = 대한임상검사과학회지, v.53 no.2, 2021년, pp.137 - 142

이규택 (녹십자의료재단 진단검사의학과) , 정무상 (제주한라대학교 임상병리과)

초록
AI-Helper

본 연구는 결핵환자의 초기 치료에서 모든 항결핵제에 감수성을 보이는 경우, 치료 과정 중 항결핵제에 대한 내성 전환을 조사하였다. 2010년 1월부터 2019년 12월까지 111개 의료기관에서 녹십자의료재단에 항결핵제감수성 검사를 의뢰한 760건의 환자를 대상으로 하였다. 항결핵제에 모두 감수성인 594명중 추적 기간에 감수성에서 내성으로 전환되는 56명을 분석한 결과 INH, RIF, SM, QUI 순으로 단독 내성 전환율이 가장 높게 나타났으며, INH, RIF에 동시에 복합 내성을 보인 경우는 56명중 17명(30.4%)으로 높은 내성 전환율을 보이고 있다. 전환 시기는 INH 항결핵제는 최소 98일부터 1,862일, 평균 435.6일이며, RIF 항결핵제는 최소 108일부터 1,673일, 평균 457.7일로 분석되었다. 이에 본 연구는 결핵 초기 치료 후 모든 항결핵제에 감수성을 보였다면 3개월이 지난 시점에서 반드시 항결핵제 감수성 검사를 통해 내성 전환 및 다제내성결핵을 확인해야만 한다고 사료되며, 국민보건향상과 국민건겅증진을 위한 국가결핵관리 사업에 도움이 되었으면 한다.

Abstract ▼ AI-Helper

This study investigated the patterns of acquiring anti-mycobacterial resistance in individuals who were susceptible to all anti-mycobacterial drugs in their initial treatment. From 2010 to 2019, anti-mycobacterial drug susceptibility tests were conducted on patients who were referred to the Green Cross Laboratories. The test results of 594 anti-mycobacterial drug sensitivity tests were collected at 111 medical institutions. The first test results had 594 cases in which all anti-mycobacterial drugs were susceptible. Isoniazid (INH), rifampin (RIF), streptomycin (SM), and quinolone (QUI) showed the highest single-resistant conversion rates. Out of 56 patients, 17 patients (30.4%) showed a high conversion rate of resistance to both INH and RIF. The tracking period was analyzed from a minimum of 98 days to 1,862 days, and an average of 435.6 days for INH, and a minimum of 108 days to 1,673 days, with an average of 457.7 days for RIF. In the case of tuberculosis patients who are susceptible to all anti-mycobacterial drugs, it is considered that the conversion to resistant and multi-drug resistant tuberculosis (MDR-TB) must be confirmed through an anti-mycobacterial susceptibility test after 3 months. It is hoped that this study will help the national tuberculosis management project to improve public health.

주제어

표/그림 (2)

표 Table 1. Pattern and average tracking period days of acquiring anti-mycobacterial resistance in susceptible M. tuberculosis using the phenotypic susceptibility
표 Table 2. Frequency and average tracking period days of acquiring anti-mycobacterial resistance in susceptible M. tuberculosis using the phenotypic susceptibility

참고문헌 (27)

Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention, 2020 March. p16-59.
Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002
Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. https://doi.org/10.1056/NEJM199806043382301

상세보기
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427

상세보기
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. https://doi.org/10.1056/NEJM200104263441706

상세보기
World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: emergency update 2008. Geneva, Switzerland; World Health Organization, 2008.
David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810-814. https://doi.org/10.1128/aem.20.5.810-814.1970

상세보기
Meacci F, Orru G, Iona E, Giannoni F, Piersimoni C, Pozzi G, et al. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol. 2005;43: 3114-3120. https://doi.org/10.1128/jcm.43.7.3114-3120.2005

상세보기
Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373:1861-1873. https://doi.org/10.1016/S0140-6736(09)60331-7

상세보기
Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med. 2010;363:1050-1058. https://doi.org/10.1056/NEJMra0908076

상세보기
Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671. https://doi.org/10.1001/jama.271.9.665

상세보기
Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 1st ed. Seoul; Korea Centers for Disease Control and Prevention, 2011:34-36.
Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007;11:571-576.
Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704

상세보기
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167: 603-662. https://doi.org/10.1164/rccm.167.4.603

상세보기
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med. 2006;174: 935-952. https://doi.org/10.1164/rccm.200510-1666st

상세보기
Singh J, Garg PK, Tandon RK. Hepatotoxicity due to anti-tuberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol. 1996;22:211-214. https://doi.org/10.1097/00004836-199604000-00012

상세보기
World Health Organization. Guidelines for treatment of tuberculosis, fourth edition. Geneva, Switzerland; World Health Organization, 2010.
Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh YS, et al. Comparison of effectiveness and adverse reactions between isoniazid 300 mg and 400 mg in korean patients with pulmonary tuberculosis. Tuberc Respir Dis. 2006;60:44-48. https://doi.org/10.4046/trd.2006.60.1.44

원문보기 상세보기
Oh SH, Kim YJ, Park SK, Hwang SH, Kim HH, Lee EY, et al. Comparison of anti-mycobacterial drug susceptibility test results by institutes and methods. Korean J Clin Microbiol. 2008;11: 43-48. https://doi.org/10.5145/kjcm.2008.11.1.43

상세보기
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320-1330.
Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 4th ed. Seoul; Korea Centers for Disease Control and Prevention, 2020 May. p13-15.
Kim JY, Park YJ, Lee NY, Chang CL, Lee MA, Shin JH. Anti-tuberculosis drug resistant rates in Mycobacterium tuberculosis isolated from respiratory specimens: A multicenter study in Korea. Ann Clin Microbiol. 2013;16:1-7. https://doi.org/10.5145/acm.2013.16.1.1

상세보기
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7:249-259. https://doi.org/10.1016/s2213-2600(18)30426-0

상세보기
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380:1201-1213. https://doi.org/10.1056/NEJMoa1811867

상세보기
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5:291-360. https://doi.org/10.1016/S2213-2600(17)30079-6

상세보기
Chang KC, Nuermberger E, Sotgiu G, Leung CC. New drugs and regimens for tuberculosis. Respirology. 2018;23:978-990. https://doi.org/10.1111/resp.13345

상세보기

저자의 다른 논문 :

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증